Thursday 08 September 2022

Le plan France Relance et la préservation de l'emploi de R&D en santé.

Cette mesure permettra de conserver les capacités humaines de R&D des entreprises françaises en difficulté suite la crise sanitaire, en contribuant au financement de salaire de personnels, et en facilitant l’emploi de jeunes diplômés à travers des collaborations entre des laboratoires Inserm et les entreprises.

L’Inserm dispose ainsi d’un financement lui permettant de préserver ou de créer plus de 200 emplois R&D dans les entreprises ou ses laboratoires dans le domaine de la Santé. Inserm Transfert, la filiale de l'Institut dédiée à la valorisation, sera le point de contact des entreprises qui souhaitent bénéficier des crédits du plan France relance pour créer, relancer ou renforcer, des partenariats de recherche avec des équipes Inserm.

Un élément indispensable : un programme de recherche collaboratif

• Un programme de recherche collaboratif encadré par un accord de collaboration est l’élément indispensable à la mise en œuvre du dispositif.

Préservation de l’emploi R&D grâce à 2 mesures :

• Prise en charge d’une partie de la rémunération des personnels R&D du privé déjà en poste dans la société.
• Recrutement de jeunes diplômés par l’Inserm.

https://www.inserm-transfert.fr/industriels/plan-france-relance/

https://www.inserm.fr/nous-connaitre/inserm-et-plan-france-relance/

Thursday 15 September 2022

The Alzheimer's Drug Discovery Foundation (ADDF):  Diagnostics Accelerator-Peripheral Biomarkers Program

The Diagnostics Accelerator is accepting applications on a rolling basis.

Exploratory awards: up to approximately $250,000

Proof-of-principle awards: up to $500,000

Validation awards: Award amounts will be based on stage and scope of research

Modalities: Blood and other peripheral markers, including saliva, urine, and ocular biomarkers are encouraged. The development of Cerebrospinal fluid (CSF) and neuroimaging biomarkers will not be considered for this program; however, we encourage the use of these modalities to validate proposed biomarkers.

Biomarker targets: Proposed approaches will be evaluated on biological plausibility linking the biomarker to disease pathophysiology. Examples of target areas of interest include, but are not limited to:

• Vascular injury and blood-brain barrier integrity
• Neuroinflammation
• Neuroprotection and Neurodegeneration
• Biomarkers of interest in fronto-temporal degeneration (FTD)
• Protein misfolding
• Synaptic integrity and/or activity
• Mitochondria and metabolic function

Other novel approaches that are supported by compelling evidence that demonstrate a rational biological connection to the disease process are encouraged.

Sample sharing program: Clinical validation of a biomarker requires well characterized samples across multiple cohorts. The Diagnostics accelerator has partnered with Janssen/Shionogi, Eisai and Roche pharmaceuticals to make available samples from their clinical trials to our researchers.

The peripheral RFP is open to all biomarker categories that will advance drug development for Alzheimer's and related dementias. The expected context of use, which defines a biomarker's intended use clinically as a diagnostic or in drug development, should be described in the application. These categories, as defined by the FDA, include diagnostic, monitoring, predictive, prognostic, pharmacodynamic/response, safety, and susceptibility/risk biomarkers. Additionally, the applicant should articulate where in the path to commercialization the study falls and what is the proposed plan forward.

The following types of projects will be supported through this RFP:

1. Exploratory awards will support pilot studies that aim to test the utility of an existing fluid biomarker approach for the first time in an Alzheimer's disease or related dementia population. These projects should already have preliminary human data from another disease indication. A limited number of awards will be considered in this category.
   Generally, projects at this stage will be awarded up to approximately $250,000 based on stage and scope of research. However, this is not a cap and higher funding levels will be considered if the proposed budget is well justified.
2. Proof-of-principle awards will support exploratory analyses of biomarkers at a small scale (e.g., 50-100 human samples) that are supported by human data demonstrating that the candidate markers correspond with disease pathophysiology. Preliminary assay validation data for the proposed studies should be included.
   Generally, projects at this stage will be awarded up to $500,000 based on stage and scope of research. However, if there is a compelling reason to go above this level, please justify this in your full proposal if invited.
3. Validation awards will support biomarkers that need to be tested at a larger scale (e.g., 500-1000 samples) and are supported by a significant body of human data demonstrating that the biomarker(s) correspond with disease pathophysiology. Applicants should be able to address how validation studies would move the biomarker towards the clinic and should define their strategies for regulatory approval and commercial scale-up. Assays should be well developed. Proposals should consider compatibility with existing sampling infrastructure, scalability, and intellectual property position, and standard operating procedures should be in place. Validation studies should compare peripheral analytes to quantitative measurements using PET and/or CSF, going beyond comparisons to cognition alone. Award amounts will be based on stage and scope of research.

Projects that succeed in the exploratory or proof-of-principle stage may be eligible for follow-on funding.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/diagnostics-accelerator-peripheral-biomarkers-program

Friday 16 September 2022

Funding opportunities from International Foundations

On this page discover the funding opportunities of international foundations according to your activity topics

Below the exel version

Friday 16 September 2022

Financial support to the organization of scientific events

More information : please download the document

Thursday 22 September 2022

The Alzheimer's Drug Discovery Foundation (ADDF): Diagnostics Accelerator-Digital Biomarkers Program

The Diagnostics Accelerator is accepting applications on a rolling basis.

Exploratory awards: up to approximately $250,000

Proof-of-principle awards: up to $500,000

Validation awards: Award amounts will be based on stage and scope of research

Platforms : A variety of digital platforms such as portables, sensors, or software are encouraged. The proposed platform should have the potential to be easily deployed at scale. Passive approaches to data collection are encouraged.

Examples of digital approaches include, but are not limited to:

• Wearables devices (e.g., smart watch)
• Mobile/tablet apps
• Smart home systems
• Virtual and augmented reality platforms
• Desktop/web apps

The following is out of scope for this RFP:

• Diagnostic hardware for traditional digital imaging platforms (e.g. optical coherence tomography, neuroimaging)
• Proposals focused on speech and language biomarkers

Note: The DxA is currently developing a speech and language biomarker consortium. Proposals outside this effort will not be considered at this time.

Symptom Domains : The RFP encourages digital biomarkers emerging from one or more of the symptom domains below. Proposed approaches will be evaluated based on the existing evidence around the biological link of the symptom domain to disease and how measuring the proposed symptom domain will improve current screening or monitoring methods in patients.

Symptom domains of interest include, but are not limited to:

• Cognition (e.g. memory, processing speed, executive function, or geolocation)
• Activities of Daily Living (instrumental basic activities or higher order activities)
• Motor function (e.g. gait, body motion, or fine motor skills including tapping, swiping, and tracing on touchscreens)
• Sensory Acuity (e.g. hearing, smell)
• Affect (e.g. mood, facial expression)
• Sleep Patterns and Characteristics
• Oculomotor (e.g. eye movement)
• Pain Assessment
• Autonomic Nervous Function (e.g. heart rate, galvanic skin response)

Combinations of these or other symptom domains with a clear link to the disease are also encouraged.

Three stages of projects will be supported through this program:

1. Exploratory awards will support pilot studies that aim to test the utility of an existing digital technology for the first time in an Alzheimer's disease or related dementia population. These projects should already have preliminary human data from another disease indication. For example, a pilot study would test a wearable gait monitoring device that has been tested in subjects with multiple sclerosis and is now being proposed to test in patients at risk for Alzheimer's. Only proposals with evidence demonstrating their technology or prototype can reliably capture, process, store, and transfer data from a clinical population will be considered. A limited number of awards will be considered in this category.
   Generally, projects at this stage will be awarded up to approximately $250,000 based on stage and scope of research. However, this is not a cap and higher funding levels will be considered if the proposed budget is well justified.

2. Proof-of-principle awards will support projects that demonstrate feasibility and/or verify that a certain approach has potential for use in Alzheimer's disease or related dementias. Preliminary data from human subjects with the proposed indication is expected. For example, the disruption of sleep is an early change seen in Alzheimer's disease and a proof-of-principle project testing a device that is capable of detecting the stages and fragmentation of sleep would build on preliminary data acquired in the proposed patient population and proposed context of use, in addition to expanding the number of patients (e.g. ~100-200 subjects) tested with the sleep tracking device. Data must be provided demonstrating that the technology or prototype is capable of the reliable capture, processing, storage, and transfer of valid data to test in the clinical population.
   Generally, projects at this stage will be awarded up to approximately $500,000 based on stage and scope of research. However, this is not a cap and higher funding levels will be considered if the proposed budget is well justified.

3. Validation awards will support projects that require testing at a larger scale and access to patients of varying demographic diversity to demonstrate clinical relevance. The technology must be verified and validated. Data quantifying the accuracy, precision, consistency, and uniformity of the technology must be provided. Applicants will be required to address scalability considerations, clinical integration plans, and anticipated regulatory considerations and commercialization. Data sharing policies and standards, intellectual property restrictions, and standard operating procedures should be well defined. Validation studies should prioritize comparisons using existing gold standard approaches to diagnose and monitor such as neuroimaging and/or CSF measurements, as well as clinical tests such as cognition, but this is dependent on the context of use. These studies will require a comprehensive experimental plan with larger sample size (e.g. 500-1000+ subjects based on power analyses). Award amounts will be based on the stage and scope of the research.

Projects that succeed in the exploratory or proof-of-principle stage may be eligible for follow-on funding in the form of a validation award.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/diagnostics-accelerator-digital-biomarkers-program

Thursday 29 September 2022

NIH Funding Opportunities

NIH Funding Opportunities (Foreign Institutions are eligible to apply) / Financements NIH ouverts aux institutions non-US

Ensemble d'appels d'offres ouverts aux institutions non-US, on this page, a set of calls for proposals that are open to non-US institutions

Friday 30 September 2022

EIT Health Call for proposals: Innovation projects and Education programmes

The publication of this call is the beginning of a journey connecting those who understand and can identify the needs with those who have the solution to ultimately deliver value to patients and citizens, as well as to our healthcare systems by and large.

See complete version

Friday 30 September 2022

ARSEP: Working Visits

To facilitate exchanges between clinical centres and/or laboratories involved in MS. Travel may be within, to, or from France.

• The training period can be up to 6 months.
• Funding requests for up to 6.000 € to cover travel and accommodation are permitted.

Deadline: No deadline - throughout the year

https://www.arsep.org/fr/220-calls-for-proposals.html

https://www.arsep.org/library/media/other/Scientifique/Regulation-Working-visits-Travel-Grants-website.pdf

Friday 30 September 2022

Alzheimer's Drug Discovery Foundation: Neuroimaging and CSF Biomarker Program

3 Deadlines:

-Letter of Intent: February 4, 2022

Invited Full Proposal: April 8, 2022

-Letter of Intent: May 20, 2022

Invited Full Proposal: July 22, 2022

-Letter of Intent: September 30, 2022

Invited Full Proposal: December 2, 2022

Award Amount: Up to $600,000 based on stage and scope of research.

Award Duration: One year with potential for follow-on funding.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers

Sunday 16 October 2022

The National Institute on Aging (NIA): PAS-19-393 Area of Focus Systems Biology (R03 Clinical Trial Not Allowed)

The application deadlines are:

• February 16, 2022
• June 16, 2022 and
• October 16, 2022

Awards are two years of funding totaling $200,000

https://grants.nih.gov/grants/guide/pa-files/PAS-19-393.html

https://www.afar.org/grants/small-research-grant-program-for-the-next-generation-of-researchers-in-ad

Sunday 16 October 2022

The National Institute on Aging (NIA): PAS-19-392 Small Research Grant Program for the Next Generation of Researchers in Alzheimer's Disease (R03)

The application deadlines are:

• February 16, 2022
• June 16, 2022 and
• October 16, 2022

Awards are two years of funding totaling $200,000

https://grants.nih.gov/grants/guide/pa-files/PAS-19-392.html

https://www.afar.org/grants/small-research-grant-program-for-the-next-generation-of-researchers-in-ad

Tuesday 18 October 2022

La Fondation Bettencourt Schueller : Impulscience

La Fondation accompagne financièrement chaque projet sur une durée de 5 ans à hauteur de 2 millions d’euros, auxquels s’ajoutent la prise en charge des frais de gestion et la prime personnelle du chercheur.

Le premier appel à candidatures aura lieu en 2022.

Impulscience est ouvert aux chercheurs et chercheuses remplissant les conditions suivantes :

• présenter un projet de recherche innovant dans les sciences de la vie ;
• avoir répondu et avoir été sélectionné lors des appels à projets Starting, Consolidator ou Advanced de l’ERC de l’année précédente mais sans avoir obtenu le financement de l’ERC (classé A à l’issue de la seconde étape de l’évaluation ERC) ;
• avoir moins de 50 ans au 1er janvier de l’année durant laquelle la candidature est évaluée par la Fondation Bettencourt Schueller et présenter sa candidature au minimum 5 ans après la date d’obtention du doctorat ;
• travailler dans un laboratoire public en France au moment de la candidature ou au plus tard au moment du début du projet.

https://www.fondationbs.org/fr/sciences-de-la-vie/soutien-aux-chercheurs/impulscience

Tuesday 01 November 2022

The Focused Ultrasound Foundation

We fund high risk or clinically based investigator-initiated projects through the External Awards Program. We also fund projects in high-priority applications of FUS through the Brain Program, Cancer Immunotherapy Program, and Veterinary Program, including both invited and investigator-initiated projects.

Brain program: It is the ultimate goal of the Foundation's Brain Program to see focused ultrasound become a standard of care for the treatment of a range of neurological disorders, including movement disorders, brain tumors, epilepsy and stroke.

The External Awards Program provides funding for investigator-initiated clinical, preclinical, and early-stage research projects through a competitive peer-reviewed application process.

The program has two tracks:

* The Pre-Clinical Track is geared primarily towards preclinical studies and research projects that target a particular clinical indication or organ. It is meant to fund research that could lead the way to a new reimbursable clinical application for image-guided FUS within five to seven years.

*The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research that, if successful, could have a profound impact on the field of focused ultrasound and that could change the way many conditions are treated.

**Additionally, the External Awards Program accepts abstracts for Clinical Trial funding requests. The abstract form for Clinical Trials is linked in the Materials section below. Funding for clinical trials is not limited to $100,000 and one year.

Funding: one-year awards totaling approximately $100,000

The Pre-Clinical Track typically does not fund large capital purchases, cannot fund overhead or institutional expenses, and will not fund the development of new focused ultrasound equipment

Application Process

Step 1: A one-page Research Abstract must be submitted at least two weeks prior to the program’s quarterly application deadlines (Feb. 1, May 1, Aug. 1, and Nov. 1).

Step 2: The Foundation will invite full Research Proposals from authors of approved Research Abstracts.

Funding decisions are returned to the applicant approximately three months after their application deadline.

https://fusfoundation.org/for-researchers/external-research-awards-program/apply-for-funding

https://fusfoundation.org/for-researchers/external-research-awards-program

Questions?

Please contact Matt Eames, PhD, Director of External Research, at meames@fusfoundation.org.